Absci Corp ABSI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ABSI is a good fit for your portfolio.
News
-
Absci to Report Business Updates and First Quarter 2024 Financial and Operating Results on May 14, 2024
-
Absci to Participate in the 23rd Annual Needham Virtual Healthcare Conference
-
Thinking about buying stock in Curiositystream, Capricor Therapeutics, PowerFleet, Absci, or Nano-X Imaging?
-
Absci Reports Business Updates and Fourth Quarter and Full Year 2023 Financial and Operating Results
-
Absci Announces Closing of Public Offering of Common Stock Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
-
Absci Announces Pricing of Public Offering of Common Stock
-
Absci Announces Proposed Public Offering of Common Stock
-
Absci Initiates IND-Enabling Studies for ABS-101, a Potential Best-in-Class Anti-TL1A Antibody de novo Designed and Optimized Using Generative AI
Trading Information
- Previous Close Price
- $4.71
- Day Range
- $4.74–4.88
- 52-Week Range
- $1.12–6.72
- Bid/Ask
- $4.72 / $4.74
- Market Cap
- $534.60 Mil
- Volume/Avg
- 33,925 / 1.6 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 75.81
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 156
- Website
- https://www.absci.com
Comparables
Valuation
|
Metric
|
ABSI
|
OABI
|
ABCL
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.49 | 1.72 | 1.01 |
Price/Sales | 75.81 | 13.54 | 30.49 |
Price/Cash Flow | — | — | — |
Price/Earnings
ABSI
OABI
ABCL
Financial Strength
|
Metric
|
ABSI
|
OABI
|
ABCL
|
|---|---|---|---|
Quick Ratio | 3.38 | 3.93 | 6.93 |
Current Ratio | 4.08 | 4.11 | 7.33 |
Interest Coverage | −108.37 | — | — |
Quick Ratio
ABSI
OABI
ABCL
Profitability
|
Metric
|
ABSI
|
OABI
|
ABCL
|
|---|---|---|---|
Return on Assets (Normalized) | −30.28% | −7.75% | −6.10% |
Return on Equity (Normalized) | −35.93% | −9.40% | −7.74% |
Return on Invested Capital (Normalized) | −32.71% | −9.83% | −10.03% |
Return on Assets
ABSI
OABI
ABCL
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Mpmsglrvtl | Wkf | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Zggqywq | Jbqywz | $104.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Nkvszxkm | Stryzm | $99.6 Bil | |
MRNA
| Moderna Inc | Dwhkkdw | Rdfw | $38.8 Bil | |
ARGX
| argenx SE ADR | Tjxhcsv | Dmfv | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Hzbwcfkrf | Ksc | $21.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Npstxdsg | Prqbz | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Grkbjpl | Cttssm | $17.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ksspxcxwp | Ysjwfg | $12.4 Bil | |
INCY
| Incyte Corp | Dqmspmxv | Wxxtgd | $11.9 Bil |